Human Intestinal Amino Acid Absorption and the Role of a Local RAS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-27

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to find out what role a local intestinal RAS (renin angiotensin system) plays in the context of amino acid absorption in the human intestinal tract and how this RAS and thus the amino acid absorption is influenced by the RAS-active drugs (angiotensin II AT1 receptor blockers (sartans) or ACE inhibitors).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)

NCT01252368

Healthy Participants Hypertension

COMPLETED

RAS-Peptide-Profile Study in Healthy Male Subjects

NCT01771783

RAS Peptide Profile in Healthy Volunteers

COMPLETED PHASE1

The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function

NCT00001628

Atherosclerosis Heart Failure, Congestive Hypertension +1 more

COMPLETED PHASE3

The Role of Mineralocorticoid Receptors in Vascular Function

NCT00759525

Apparent Mineralocorticoid Excess (AME)

COMPLETED PHASE2/PHASE3

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

NCT00001629

Atherosclerosis Heart Failure, Congestive Hypertension +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renin-Angiotensin Aldosterone System (RAS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RAS- active medication

Patients taking RAS- active medication (ACE- Inhibitor, Angiotensin II AT1 Antagonist (Sartan)) on a daily Basis for at least 6 months for medical reasons

biopsy of intestinal tissue

Intervention Type OTHER

4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)

blood draw

Intervention Type OTHER

40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)

urine collection

Intervention Type OTHER

Midstream Urine collection

no RAS- active medication

Patients not taking RAS- active medication

biopsy of intestinal tissue

Intervention Type OTHER

4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)

blood draw

Intervention Type OTHER

40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)

urine collection

Intervention Type OTHER

Midstream Urine collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biopsy of intestinal tissue

4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)

Intervention Type OTHER

blood draw

40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)

Intervention Type OTHER

urine collection

Midstream Urine collection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body Mass Index (BMI): 18-35 kg/m2
* cohort 1: therapy with an angiotensin II AT1 antagonist or ACE Inhibitor
* cohort 2: no therapy with an angiotensin II AT1 antagonist or ACE Inhibitor
* Carrying out a diagnostic gastroscopy, colonoscopy or a combined gastroscopy / colonoscopy
* Existence of written consent after detailed information about the study

Exclusion Criteria

* History of gastrointestinal tract surgery (except for appendectomy and inguinal hernia surgery)
* History of malignancy
* Severe acute and chronic organ diseases requiring treatment (e.g. kidney replacement therapy)
* Patients with an increased risk of bleeding (e.g. oral anticoagulation, coagulation disorders)
* Drug or alcohol abuse
* Mental impairment limiting the ability to meet all study requirements

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes